Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) CEO Christopher Peetz sold 5,209 shares of the business’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $28.03, for a total value of $146,008.27. Following the completion of the sale, the chief executive officer now directly […]
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Free Report) COO Peter Radovich sold 1,408 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $28.03, for a total transaction of $39,466.24. Following the completion of the sale, the chief operating officer now directly […]
Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its target price cut by Raymond James from $78.00 to $64.00 in a research note released on Tuesday morning, Benzinga reports. They currently have a strong-buy rating on the stock. A number of other research analysts have also recently issued reports on MIRM. JPMorgan Chase & Co. reissued […]
Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) had its target price lowered by HC Wainwright from $60.00 to $58.00 in a report published on Monday morning, Marketbeat.com reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q1 2024 earnings at ($0.13) EPS, Q2 2024 earnings at […]
By Adriano Marchese Mirum Pharmaceuticals said Monday that data from a Phase 2 trial for its potential biliary atresia treatment Livmarli didn't meet either.